keyword
MENU ▼
Read by QxMD icon Read
search

HCV guidelines

keyword
https://www.readbyqxmd.com/read/29343192/coverage-and-outcomes-of-antenatal-tests-for-infections-a-population-based-survey-in-the-province-of-trento-italy
#1
Michela Dalmartello, Fabio Parazzini, Mariangela Pedron, Riccardo Pertile, Lucia Collini, Carlo La Vecchia, Silvano Piffer
BACKGROUND: Rubella, syphilis, toxoplasmosis, cytomegalovirus (CMV), hepatitis B (HBV) and C (HCV), HIV, and Group B Streptococcus (GBS) infections may have very severe outcomes during pregnancy, and for this reason, monitoring of infections in pregnant women is a requirement of prenatal assistance. AIMS: To describe coverage and outcome of the screening for rubella, syphilis, toxoplasmosis, CMV, HBV, HCV, HIV, and Group B Streptococcus in pregnancy in the Autonomous Province of Trento, Northern Italy (538,600 inhabitants)...
January 17, 2018: Journal of Maternal-fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/29327821/chronic-kidney-disease-in-patients-with-chronic-hepatitis-c-virus-infection
#2
Omer Shahab, Pegah Golabi, Zobair M Younossi
Hepatitis C virus (HCV) infection affects many organs in the body, including the liver, kidneys, skin, joints and others. Although the hepatic manifestation of HCV has been widely studied, the extrahepatic manifestaions of HCV have not been fully appreciated. Studies have shown that patients with HCV have a higher risk of chronic kidney disease and end-stage renal disease, as well as poorer outcomes after kidney transplantation. Given these findings, it is important to screen HCV patients for presence of renal impairement in a timely manner...
January 10, 2018: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29318374/role-of-ribavirin-in-the-treatment-of-hepatitis-c-virus-associated-mixed-cryoglobulinemia-with-interferon-free-regimens
#3
Lucio Boglione, Jessica Cusato, Simone Mornese Pinna, Amedeo De Nicolò, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
Mixed cryoglobulinemia (MC) is the most common extrahepatic manifestation of chronic hepatitis C (CHC), with the presence of symptoms in 10-15% of cases. There have been encouraging data regarding immunological and clinical responses in patients treated with the novel combinations of direct-acting antivirals (DAAs), but the role of ribavirin (RBV) in the treatment of MC has not yet been demonstrated. We prospectively enrolled 132 patients affected by MC and CHC, and virological, immunological and clinical responses were evaluated at 12 weeks after completion of treatment...
January 9, 2018: Archives of Virology
https://www.readbyqxmd.com/read/29317673/the-epidemiology-of-hepatitis-c-virus-in-iran-systematic-review-and-meta-analyses
#4
Sarwat Mahmud, Vajiheh Akbarzadeh, Laith J Abu-Raddad
The aim of this study was to characterize hepatitis C virus (HCV) epidemiology in Iran and estimate the pooled mean HCV antibody prevalence in different risk populations. We systematically reviewed and synthesized reports of HCV incidence and/or prevalence, as informed by the Cochrane Collaboration Handbook, and reported our findings following the PRISMA guidelines. DerSimonian-Laird random effects meta-analyses were implemented to estimate HCV prevalence in various risk populations. We identified five HCV incidence and 472 HCV prevalence measures...
January 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29315640/virological-patterns-of-hcv-patients-with-failure-to-interferon-free-regimens
#5
Starace Mario, Minichini Carmine, De Pascalis Stefania, Macera Margherita, Occhiello Laura, Messina Vincenzo, Sangiovanni Vincenzo, Adinolfi Luigi Elio, Claar Ernesto, Precone Davide, Stornaiuolo Gianfranca, Stanzione Maria, Ascione Tiziana, Caroprese Mara, Zampino Rosa, Parrilli Gianpaolo, Gentile Ivan, Brancaccio Giuseppina, Iovinella Vincenzo, Martini Salvatore, Masarone Mario, Fontanella Luca, Masiello Addolorata, Evangelista Sagnelli, Punzi Rodolfo, Salomone Megna Angelo, Santoro Renato, Gaeta Giovanni Battista, Coppola Nicola
BACKGROUND: The study characterized the virological patterns and the resistance-associated substitutions (RASs) in patients with failure to IFN-free regimens enrolled in the real-life setting. PATIENTS AND METHODS: All 87 consecutive HCV patients with failed IFN-free regimens, observed at the laboratory of the University of Campania, were enrolled. All patients had been treated with DAA regimens according to the HCV genotype, international guidelines and local availability...
January 9, 2018: Journal of Medical Virology
https://www.readbyqxmd.com/read/29314090/development-and-validation-of-lc-ms-ms-method-for-simultaneous-determination-of-sofosbuvir-and-daclatasvir-in-human-plasma-application-to-pharmacokinetic-study
#6
Ola M Abdallah, Ahmed M Abdel-Megied, Amira S Gouda
The first simple and highly sensitive Liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method was developed and fully validated for the simultaneous determination of newly discovered antiviral drugs namely, Sofosbuvir (SOF) and Daclatasvir (DAC) in human plasma. Tadalafil (TAD) was used as internal standard (IS). SOF, DAC and TAD (IS) were extracted from plasma using liquid-liquid extraction technique with methyl tert-butyl ether. The chromatographic separation was carried out using ZorbaxSB-C18 column (4...
January 3, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29311411/clinical-findings-of-hcv-chronic-infection-in-undocumented-immigrants-and-low-income-refugees-in-three-areas-of-southern-italy
#7
Evangelista Sagnelli, Loredana Alessio, Caterina Sagnelli, Luciano Gualdieri, Mariantonietta Pisaturo, Carmine Minichini, Giovanni Di Caprio, Mario Starace, Lorenzo Onorato, Gaetano Scotto, Margherita Macera, Nicola Coppola
INTRODUCTION AND AIM: In recent decades, Italy has become a land of immigration from countries suffering a socio-economic crisis. The aim of this study was to perform an organized screening to identify and offer care to immigrants with HCV infection. MATERIAL AND METHODS: The screening, performed from 2012 to 2015, involved 1,727 immigrants in the Campania and Apulia regions in southern Italy. RESULTS: Screening was accepted by 1,727 (85%) out of 2,032 immigrants interviewed; 70 (4...
December 27, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/29310928/sofosbuvir-and-velpatasvir-for-hepatitis-c-virus-infection-in-people-with-recent-injection-drug-use-simplify-an-open-label-single-arm-phase-4-multicentre-trial
#8
Jason Grebely, Olav Dalgard, Brian Conway, Evan B Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya L Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail V Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J Feld, Chris Fraser, John F Dillon, Phillip Read, Ed Gane, Gregory J Dore
BACKGROUND: Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to evaluate the efficacy of sofosbuvir and velpatasvir therapy in people with chronic HCV infection and recent injection drug use. METHODS: In this open-label, single-arm phase 4 trial (SIMPLIFY), we recruited participants with recent injection drug use (past 6 months) and chronic HCV genotype 1-6 infection from seven countries (19 sites)...
January 5, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29301497/evaluating-screening-approaches-for-hepatocellular-carcinoma-in-a-cohort-of-hcv-related-cirrhosis-patients-from-the-veteran-s-affairs-health-care-system
#9
Nabihah Tayob, Peter Richardson, Donna L White, Xiaoying Yu, Jessica A Davila, Fasiha Kanwal, Ziding Feng, Hashem B El-Serag
BACKGROUND: Hepatocellular carcinoma (HCC) has limited treatment options in patients with advanced stage disease and early detection of HCC through surveillance programs is a key component towards reducing mortality. The current practice guidelines recommend that high-risk cirrhosis patients are screened every six months with ultrasonography but these are done in local hospitals with variable quality leading to disagreement about the benefit of HCC surveillance. The well-established diagnostic biomarker α-Fetoprotein (AFP) is used widely in screening but the reported performance varies widely across studies...
January 4, 2018: BMC Medical Research Methodology
https://www.readbyqxmd.com/read/29300496/hepcare-europe-bridging-the-gap-in-the-treatment-of-hepatitis-c-study-protocol
#10
Davina Swan, Walter Cullen, Juan Macias, Cristiana Oprea, Alistair Story, Julian Surey, Peter Vickerman, John S Lambert
BACKGROUND: Hepatitis C (HCV) infection is highly prevalent among people who inject drugs (PWID). Many PWID are unaware of their infection and few have received HCV treatment. Recent developments in treatment offer cure rates >90%. However, the potential of these treatments will only be realised if HCV identification among PWID with linkage to treatment is optimised. This paper describes the Hepcare Europe project, a collaboration between five institutions across four member states (Ireland, UK, Spain, Romania), to develop, implement and evaluate interventions to improve the identification, evaluation and treatment of HCV among PWID...
January 4, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29291208/hepatitis-c-infection-in-renal-transplantation-pathogenesis-current-impact-and-emerging-trends
#11
REVIEW
Sailaja Kesiraju, Praneeth Srikanti, S Sahariah
Prevalence of hepatitis C infection, which is associated with mortality and morbidity, is higher in chronic kidney disease patients on hemodialysis and transplant recipients when compared to non HCV infected patients. In addition to the conventional risk factors, HCV infection maybe an additional risk factor in the development of chronic kidney disease. HCV causes adverse effects leading to the poor long term outcome in renal transplant recipients; hepatitis C infection can cause both hepatic as well as extra hepatic complications...
September 2017: Virusdisease
https://www.readbyqxmd.com/read/29276983/uplc-ms-ms-method-for-the-simultaneous-quantification-of-sofosbuvir-sofosbuvir-metabolite-gs-331007-and-daclatasvir-in-plasma-of-hiv-hcv-co-infected-patients
#12
Stefania Notari, Massimo Tempestilli, Gabriele Fabbri, Raffaella Libertone, Andrea Antinori, Adriana Ammassari, Chiara Agrati
Direct-acting antiviral agents (DAAs) represent the major advance in hepatitis C virus (HCV) infection treatment leading to extremely high eradication rates in HCV mono- and HIV/HCV co-infected patients. In this scenery, availability of Therapeutic Drug Monitoring (TDM) is of interest to assess plasma concentrations to prevent either therapeutic failure due to suboptimal medication adherence and drug-drug interactions or avoid adverse events. Aim of this study was to develop and validate an Ultra-Performance Liquid Chromatography Mass Spectrometry (UPLC-MS/MS) method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007), and daclatasvir in human plasma...
December 12, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29274178/assessing-uncertainty-in-the-burden-of-hepatitis-c-virus-comparison-of-estimated-disease-burden-and-treatment-costs-in-the-uk
#13
Finn Gubay, Roisin Staunton, Cornelia Metzig, Ibrahim Abubakar, Peter J White
Hepatitis C virus (HCV) is a major and growing public health concern. We need to know the expected health burden and treatment cost, and understand uncertainty in those estimates, to inform policy-making and future research. Two models that have been important in informing treatment guidelines and assessments of HCV burden were compared by simulating cohorts of individuals with chronic HCV infection initially aged 20, 35, and 50 years. One model predicts that health losses (measured in Quality-Adjusted Life-Years (QALYs)) and treatment costs decrease with increasing initial age of the patients, whilst the other model predicts that below 40 years, costs increase and QALY losses change little with age, and above 40 years they decline with increasing age...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29222916/transplanting-hcv-positive-livers-into-hcv-negative-patients-with-preemptive-antiviral-treatment-a-modeling-study
#14
Jagpreet Chhatwal, Sumeyye Samur, Emily D Bethea, Turgay Ayer, Fasiha Kanwal, Chin Hur, Mark S Roberts, Norah Terrault, Raymond T Chung
Under current guidelines hepatitis C virus (HCV)-positive livers are not transplanted into HCV-negative recipients because of adverse post-transplant outcomes associated with allograft HCV infection. However, HCV can now be cured post liver transplant (LT) using direct-acting antivirals (DAAs) with >90% success; therefore, HCV-negative patients on the liver transplant (LT) waiting list may benefit from accepting HCV-positive organs with preemptive treatment. Our objective was to evaluate if and in which HCV-negative patients the potential benefit of accepting an HCV-positive (i...
December 9, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29217468/availability-of-hepatitis-c-diagnostics-and-therapeutics-in-european-and-eurasia-countries
#15
Hakan Leblebicioglu, Joop E Arends, Resat Ozaras, Giampaolo Corti, Lurdes Santos, Christoph Boesecke, Andrew Ustianowski, Ann-Sofi Duberg, Simona Ruta, Nermin N Salkic, Petr Husa, Ivana Lazarevic, Juan A Pineda, Natalia Yurievna Pshenichnaya, Tengiz Tsertswadze, Mojca Matičič, Edmond Puca, Gulzhan Abuova, Judit Gervain, Ramin Bayramli, Salih Ahmeti, Mairi Koulentaki, Badreddine Kilani, Adriana Vince, Francesco Negro, Mustafa Sunbul, Dominique Salmon
BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis...
December 4, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29209789/-novel-aspects-of-the-guidelines-for-hemotherapy-2017-implications-for-anesthesiology
#16
REVIEW
I Pekrul, G Wittmann, P Möhnle
Based on the German Transfusion Law, the periodically updated guidelines "Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten" ("Hämotherapierichtlinien") are intended to provide the current knowledge and state of the art of blood transfusion practice in Germany. The novel update 2017 contains relevant changes for blood donation, especially the extension of the exclusion period of persons at risk for sexually transmitted HBV, HCV and HIV diseases to 12 months. Moreover, the guidelines provide several changes relevant to blood transfusion practice in anesthesiology, such as: all autologous hemotherapy procedures including normovolemic hemodilution, cell saver, and autologous blood donation and transfusion require formal registration at the regulatory authority...
December 5, 2017: Der Anaesthesist
https://www.readbyqxmd.com/read/29209663/electronic-medical-record-alert-improves-hcv-testing-for-baby-boomers-in-primary-care-setting-adults-born-during-1945-1965
#17
Eyad Al-Hihi, Caylin Shankweiler, David Stricklen, Cheryl Gibson, Winston Dunn
Method: This project aims to implement the HCV birth cohort screening guidelines over a 9-month period in the primary care setting at the University of Kansas Health System General Internal Medicine Division. The project team measured the number of patients in the baby boomer population who received a one-time screen for HCV. An electronic medical record (EMR) intervention was implemented to identify baby boomers who did not have an HCV screening or diagnosis. Additionally, education was provided to all primary care providers in the clinic to increase awareness of the HCV birth cohort screening...
2017: BMJ Open Quality
https://www.readbyqxmd.com/read/29197933/impact-of-low-dose-steroids-on-hba1c-levels-and-development-of-pre-diabetes-and-nodat-in-non-diabetic-renal-transplant-recipients-on-long-term-follow-up
#18
F P Tillmann, M Schmitz, L C Rump, I Quack
BACKGROUND: This study aimed to evaluate the impact of 5 mg of prednisolone/day on HbA1c levels and its association with the development of pre-diabetes and new-onset diabetes mellitus (NODAT) in non-diabetic first renal transplant recipients on long-term follow-up. METHODS: Four hundred patients were analysed on an average of 4.1 ± 3.0 years after successful transplantation: 96 (24%) were steroid-free and 304 (76%) treated with 5 mg of prednisolone/day combined with cyclosporine A (CsA) or tacrolimus (Tac) as part of their immunosuppressive protocol...
December 2, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/29185250/management-of-hepatitis-c-in-decentralised-versus-centralised-drug-substitution-programmes-and-minimally-invasive-point-of-care-tests-to-close-gaps-in-the-hcv-cascade
#19
Andrea Bregenzer, Anna Conen, Jürg Knuchel, Andrée Friedl, Franz Eigenmann, Martin Näf, Peter Ackle, Martin Roth, Christoph Andreas Fux
BACKGROUND: In Switzerland, intravenous drug use accounts for the majority of hepatitis C virus (HCV) infections. Early HCV treatment prevents further transmissions and reduces morbidity and mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programmes are often insufficiently screened and treated. AIM: The aim was to compare the current state of HCV management in centralised and decentralised drug substitution programmes of the canton Aargau...
November 29, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29169329/micro-costing-analysis-of-guideline-based-treatment-by-direct-acting-agents-the-real-life-case-of-hepatitis-c-management-in-brazil
#20
Hugo Perazzo, Marcelino Jose Jorge, Julio Castro Silva, Alexandre Monken Avellar, Patrícia Santos Silva, Carmen Romero, Valdilea Gonçalves Veloso, Ruben Mujica-Mota, Rob Anderson, Chris Hyde, Rodolfo Castro
BACKGROUND: Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA) has been associated with a financial burden to health authorities worldwide. We aimed to evaluate the guideline-based treatment costs by DAAs from the perspective of the Brazilian Ministry of Health (BMoH). METHODS: The activity based costing method was used to estimate the cost for monitoring/treatment of genotype-1 (GT1) HCV patients by the following strategies: peg-interferon (PEG-IFN)/ribavirin (RBV) for 48 weeks, PEG-IFN/RBV plus boceprevir (BOC) or telaprevir (TEL) for 48 weeks, and sofosbuvir (SOF) plus daclastavir (DCV) or simeprevir (SIM) for 12 weeks...
November 23, 2017: BMC Gastroenterology
keyword
keyword
64824
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"